| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 20, 2026 | 18d | — | — | 0 | 0 |
| Dec 18, 2026 | 46d | — | — | 0 | 0 |
| Feb 19, 2027 | 109d | — | — | 0 | 0 |
| May 21, 2027 | 200d | $2.70 | +0.00% | 10 | 10 |
polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid's anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs' therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body's target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid's pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e